Delisting of Merck Serono shares expected on July 18, 2007

Squeeze Out Successfully Completed

10-Jul-2007 - The Civil Court of Basel has cancelled all remaining publicly held shares of Merck Serono S.A. (Merck Serono) and annulled all outstanding rights to acquire such shares. Therefore, Merck now holds 100% of the shares of Merck Serono. Merck Serono's shares will be delisted from the SWX Swiss ...

Serono announces highly significant positive outcome of Rebif® vs Avonex® study in multiple sclerosis

10-May-2001 - Serono announced today the major outcomes of the direct comparative study between Rebif® (Serono S.A.) and Avonex® (Biogen Inc.) in patients with relapsing-remitting multiple sclerosis (RRMS). The primary endpoint of the study shows that patients treated with Rebif® have a 90% greater chance of ...

Serono and Evotec OAI sign assay development and screening services agreement

27-Apr-2001 - Serono S.A. (SWX Swiss Exchange: SEO and NYSE: SRA) has announced a services agreement with Evotec OAI, Hamburg, Germany (EVOTEC BioSystems AG, Neuer Markt: EVT), a supplier of integrated high-value added biological, chemical and screening programmes to the pharmaceutical and biotechnology ...

Serono: Major milestone for Multiple Sclerosis treatment in Europe

16-Mar-2001 - Worldwide, Multiple Sclerosis (MS) is the most common disease of the central nervous system in young adults with up to two million people affected (450'000 in Europe alone). The European Commission has approved the highest available dose of Rebif® (44mcg 3 times per week) and recommends it as ...

Serono initiates clinical trial of Serostim® for aids-related metabolic complication

Study to identify potential benefits of recombinant human growth hormone for HIV-Associated Adipose Redistribution Syndrome (HARS)

22-Feb-2001 - Serono, Inc. today announced the initiation of the Serostim® for Treatment of Adipose Redistribution Syndrome (STARS) study. This double blind, placebo-controlled study will evaluate Serostim® [somatropin (rDNA origin) for injection], a recombinant human growth hormone (rHGH) currently ...

SERONO INTRODUCES TWO INNOVATIVE PRODUCTS TO ITS PORTFOLIO FOR FERTILITY TREATMENT IN THE US

06-Feb-2001 - Serono S.A. (SWX Swiss Exchange: SEO and NYSE: SRA) announces the launch of two new enhancements to its portfolio of patient-friendly fertility products in the US. Both new products--Ovidrel® and Cetrotide™--contribute to making infertility treatment simpler and more convenient for patients. ...